During the development of NASH, miR-690 expression was significantly lower in mouse and human NASH livers compared to controls; the KC-specific KO of miR-690 increased NASH development, whereas miR-690 therapy restored specific KC functions by targeting NADK and led to reduced fibrosis and steatosis (45). This evidence concerns the gene NADK and metabolic dysfunction-associated steatohepatitis.